Compare WES & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WES | VTRS |
|---|---|---|
| Founded | 2007 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 12.0B |
| IPO Year | 2008 | N/A |
| Metric | WES | VTRS |
|---|---|---|
| Price | $39.46 | $10.66 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $41.20 | $11.17 |
| AVG Volume (30 Days) | 1.5M | ★ 9.6M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.26% | 4.49% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.38 | N/A |
| Revenue | $3,740,425,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $7.20 | $1.61 |
| P/E Ratio | $11.63 | ★ N/A |
| Revenue Growth | ★ 5.81 | N/A |
| 52 Week Low | $33.60 | $6.85 |
| 52 Week High | $43.33 | $13.25 |
| Indicator | WES | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 54.95 |
| Support Level | $38.60 | $10.49 |
| Resistance Level | $39.30 | $10.73 |
| Average True Range (ATR) | 0.63 | 0.32 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 77.31 | 53.28 |
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.